Advertisement

Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan

  • Tetsuhiro Tanaka
  • Masaomi Nangaku
  • Enyu Imai
  • Yoshiharu Tsubakihara
  • Masatoshi Kamai
  • Michihito Wada
  • Shinji AsadaEmail author
  • Tadao Akizawa
Correction
  • 128 Downloads

Correction to: Clinical and Experimental Nephrology  https://doi.org/10.1007/s10157-018-1632-9

In the original publication of the article, two sentences in the “Results” section were published incorrectly. The corrected texts are provided below:

  1. 1.

    In the first paragraph of the section “Effectiveness”, 10th line should read as “The administered dose of darbepoetin (mean ± SD, µg) in the effectiveness analysis”.

     
  2. 2.

    In the fourth paragraph of the section “Effectiveness”, 1st line should read as “Female patients or those with advanced age…baseline systolic blood pressure ≥ 130 mmHg”.

     

Notes

Copyright information

© Japanese Society of Nephrology 2019

Authors and Affiliations

  • Tetsuhiro Tanaka
    • 1
  • Masaomi Nangaku
    • 1
  • Enyu Imai
    • 2
  • Yoshiharu Tsubakihara
    • 3
  • Masatoshi Kamai
    • 4
  • Michihito Wada
    • 5
  • Shinji Asada
    • 5
    Email author
  • Tadao Akizawa
    • 6
  1. 1.Division of Nephrology and EndocrinologyThe University of Tokyo Graduate School of MedicineTokyoJapan
  2. 2.Internal Medicine of Nakayamadera Imai ClinicTakarazukaJapan
  3. 3.Graduate School of Health Care SciencesJikei InstituteOsakaJapan
  4. 4.Pharmacovigilance DepartmentKyowa Hakko Kirin Co., Ltd.TokyoJapan
  5. 5.Medical Affairs DepartmentKyowa Hakko Kirin Co., Ltd., Otemachi Financial City Grand CubeTokyoJapan
  6. 6.Showa UniversityTokyoJapan

Personalised recommendations